<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545438</url>
  </required_header>
  <id_info>
    <org_study_id>LIB003-001</org_study_id>
    <nct_id>NCT03545438</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003</brief_title>
  <acronym>LIB003SAD</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of LIB003 in Healthy Subjects With Hypercholesterolemia on Diet or Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIB Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LIB Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled, single ascending dose study in nine (9)
      separate and sequential dose cohorts (7 SC and 2 IV cohorts) to assess the safety and
      tolerability, pharmacokinetics and pharmacodynamics of LIB003 in subjects with moderately
      elevated LDL-C levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After meeting eligibility criteria within each cohort subjects will be randomized to receive
      a single dose of LIB003. Seven (7) cohorts will receive LIB003 escalating doses of LIB003, or
      placebo, by SC injection and 2 cohorts LIB003 or placebo by IV infusion. Dose escalation will
      be based on the assessment of safety and tolerability data. All cohorts will each first
      enroll a sentinel group of subjects who will receive LIB003 or placebo in a double-blind
      fashion with the remaining subjects in that cohort only to be dosed after the safety data on
      day 4 from the sentinel subjects has been assessed and deemed safe.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>single ascending dose with placebo controll</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Within each dosing cohort randomization is performed according to a computer-generated randomization scheme. Other than the study drug prepared by an unblinded pharmacist and administered by unblinded nurses who will be instructed not to discuss randomized treatment assignments and have no other role in the study, all study staff and PI, along with the subjects are blinded as to treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>43 days</time_frame>
    <description>safety and tolerability will be assessed by the incidence and severity of treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in serum unbound (free) proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations over time</measure>
    <time_frame>43 days</time_frame>
    <description>Serum free PCSK9 will be measured at baseline and various time points over 43 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in serum total PCSK9 over time</measure>
    <time_frame>43 days</time_frame>
    <description>Serum total PCSK9 will be measured at baseline and various time points over 43 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Low Density Lipoprotein cholesterol (LDL-C) over time</measure>
    <time_frame>43 days</time_frame>
    <description>Serum LDL-C will be measured at baseline and various time points over 43 days to derive percent change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in Apolipoprotein B (Apo B) over time</measure>
    <time_frame>43 days</time_frame>
    <description>Serum Apo B will be measured at baseline and various time points over 43 days to derive percent change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum LIB003 concentrations over time</measure>
    <time_frame>43 days</time_frame>
    <description>serum LIB003 will be measured at various time points to derive AUC (area under curve)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti LIB003 antibodies (ADAs)</measure>
    <time_frame>43 days</time_frame>
    <description>Measurement of ADAs will be done at baseline and various intervals after LIB003 administration</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LIB003 dose 1 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LIB003 dose 2 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LIB003 dose 4 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LIB003 dose 4 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LIB003 dose 5 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LIB003 dose 4 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LIB003 dose 5 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 8</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LIB003 dose 3 SC - statin treated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 9</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LIB003 dose 4 SC - statin treated</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LIB003</intervention_name>
    <description>LIB003 or placebo</description>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_label>cohort 4</arm_group_label>
    <arm_group_label>cohort 5</arm_group_label>
    <arm_group_label>cohort 6</arm_group_label>
    <arm_group_label>cohort 7</arm_group_label>
    <arm_group_label>cohort 8</arm_group_label>
    <arm_group_label>cohort 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women who are &gt;/=18 and &lt;/=70 years of age. Female subjects must be of
             non-childbearing potential.

          -  LDL-C &gt;/=100 mg/dL who are either not on a lipid-lowering therapy or who are on stable
             statin therapy.

          -  Body mass index (BMI) &gt;18 and &lt;38 kg/m2

          -  Mild hypertensives on a stable dose of no more than one antihypertensive drug

        Exclusion Criteria:

          -  History of any prior or concomitant clinical condition or acute and/or unstable
             systemic disease compromising subject inclusion

          -  Systolic blood pressure &lt;90 mmHg or &gt;160 mmHg or diastolic blood pressure &lt;50 or &gt;100
             mmHg at screening

          -  Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface
             antigen, or hepatitis C virus antibody

          -  Abnormal liver function test at Screening (aspartate aminotransferase [AST] or alanine
             aminotransferase [ALT] &gt;2 Ã— the upper limit of normal [ULN]

          -  Estimated glomerular filtration rate &lt;60 mL/min/1.73 m2 at screening, as determined by
             the CKD-EPI Equation

          -  History of prescription drug abuse, illicit drug use (including marijuana), or alcohol
             abuse

          -  Unable to spend 4 days in confinement unit

          -  History of allergy to protein-based biologics including, but not limited to, mAbs and
             vaccine

          -  Any other finding which, in the opinion of the Investigator, would compromise the
             subject's safety or participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Traci A Turner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medpace Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medpace (MARC/CPU)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03545438/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

